Rasburicase: a potent uricolytic agent - PubMed (original) (raw)
Review
Rasburicase: a potent uricolytic agent
Ching-Hon Pui. Expert Opin Pharmacother. 2002 Apr.
Abstract
Rasburicase (Fasurtec, Elitek, Sanofi-Synthelabo) is a new recombinant urate oxidase developed for the prevention and treatment of hyperuricaemia. It has a half-life of 17-21 h and produces rapid (within 4 h) and pronounced reductions in plasma uric acid concentrations. To date, rasburicase has been tested in four clinical trials conducted in patients with cancer (primarily haematological malignancies). It successfully alleviated hyperuricaemia in 98% of patients and prevented this complication in 99.6% of those who were at risk. In a stratified, randomised trial, rasburicase was more effective than allopurinol. Most patients had improved or stabilised renal function during rasburicase treatment, despite ongoing chemotherapy-induced tumour lysis. Except for occasional instances of haemolytic anaemia and methemoglobinaemia in patients with glucose-6-phosphate dehydrogenase deficiency, rasburicase was well-tolerated, with a low frequency of mild adverse events. Rasburicase is a safe and effective agent in the prevention or treatment of hyperuricaemia in cancer patients.
Similar articles
- Rasburicase: a review of its use in the management of anticancer therapy-induced hyperuricaemia.
Oldfield V, Perry CM. Oldfield V, et al. Drugs. 2006;66(4):529-45. doi: 10.2165/00003495-200666040-00008. Drugs. 2006. PMID: 16597166 Review. - Spotlight on rasburicase in anticancer therapy-induced hyperuricemia.
Oldfield V, Perry CM. Oldfield V, et al. BioDrugs. 2006;20(3):197-9. doi: 10.2165/00063030-200620030-00008. BioDrugs. 2006. PMID: 16724869 Review. - [Rasburicase (Fasturtec)].
Vogt B, Gugger M, Frey FJ. Vogt B, et al. Ther Umsch. 2004 Sep;61(9):579-82. doi: 10.1024/0040-5930.61.9.579. Ther Umsch. 2004. PMID: 15493120 German. - Rasburicase.
Easton J, Noble S, Jarvis B. Easton J, et al. Paediatr Drugs. 2001;3(6):433-7; discussion 438-9. doi: 10.2165/00128072-200103060-00004. Paediatr Drugs. 2001. PMID: 11437188 - Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study.
Bosly A, Sonet A, Pinkerton CR, McCowage G, Bron D, Sanz MA, Van den Berg H. Bosly A, et al. Cancer. 2003 Sep 1;98(5):1048-54. doi: 10.1002/cncr.11612. Cancer. 2003. PMID: 12942574 Clinical Trial.
Cited by
- Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype.
Gammal RS, Pirmohamed M, Somogyi AA, Morris SA, Formea CM, Elchynski AL, Oshikoya KA, McLeod HL, Haidar CE, Whirl-Carrillo M, Klein TE, Caudle KE, Relling MV. Gammal RS, et al. Clin Pharmacol Ther. 2023 May;113(5):973-985. doi: 10.1002/cpt.2735. Epub 2022 Sep 24. Clin Pharmacol Ther. 2023. PMID: 36049896 Free PMC article. - The Role of the Intestine in the Development of Hyperuricemia.
Yin H, Liu N, Chen J. Yin H, et al. Front Immunol. 2022 Feb 24;13:845684. doi: 10.3389/fimmu.2022.845684. eCollection 2022. Front Immunol. 2022. PMID: 35281005 Free PMC article. Review. - Revisiting the Effects of Xenon on Urate Oxidase and Tissue Plasminogen Activator: No Evidence for Inhibition by Noble Gases.
Cahill J, Ruffing AM. Cahill J, et al. Front Mol Biosci. 2020 Sep 11;7:574477. doi: 10.3389/fmolb.2020.574477. eCollection 2020. Front Mol Biosci. 2020. PMID: 33024747 Free PMC article. - Tumor lysis syndrome in childhood malignancies.
Cheung WL, Hon KL, Fung CM, Leung AK. Cheung WL, et al. Drugs Context. 2020 Feb 25;9:2019-8-2. doi: 10.7573/dic.2019-8-2. eCollection 2020. Drugs Context. 2020. PMID: 32158483 Free PMC article. Review. - Catalytic Mechanisms for Cofactor-Free Oxidase-Catalyzed Reactions: Reaction Pathways of Uricase-Catalyzed Oxidation and Hydration of Uric Acid.
Wei D, Huang X, Qiao Y, Rao J, Wang L, Liao F, Zhan CG. Wei D, et al. ACS Catal. 2017 Jul 7;7(7):4623-4636. doi: 10.1021/acscatal.7b00901. Epub 2017 Jun 15. ACS Catal. 2017. PMID: 28890842 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources